Ann: Chimeric partnering with Cell Therapies Australia, page-14

I still expect some sort of RAD raising but who knows. RAD hitting an EGM roadblock delay, not sure whether that is significant or not. Had expected the CR here already done and dusted due to Sep deadline.

Fact is CHM needs urgent funding to continue but sure as well that Hopper won't let this one go down the drain.

Like having Space X rocket on the launch pad with no fuel. Anyone who sees value could grab it at any second, question is why isn't anyone when the clinical and pre-clinical data are so compelling and all the trial obstacles have been removed.

NEU and ACW results were interpreted by the market as crap, CHM already valued as such.

GLTA